Moderate to Severe Forehead Lines, Lateral Canthal Lines, and Glabellar Lines
Moderate to severe forehead lines
Actual patient. Results may vary.
Photos taken at maximum eyebrow elevation before treatment with BOTOX® Cosmetic (onabotulinumtoxinA) and taken at maximum eyebrow elevation after treatment with BOTOX® Cosmetic at day 30.
In clinical trials at day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects. (1)
Moderate to severe crow’s feet lines
Actual patient. Results may vary.
Photos taken at maximum smile before treatment with BOTOX® Cosmetic (onabotulinumtoxinA) and taken at maximum smile after
treatment with BOTOX® Cosmetic at day 30.
In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in crow’s feet line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects. (1)
Moderate to severe frown lines
Actual patient. Results may vary.
Photos taken at maximum frown before treatment with BOTOX® Cosmetic (onabotulinumtoxinA) and taken at maximum frown after treatment with BOTOX® Cosmetic at day 30.
In clinical trials at day 30, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo, as assessed by investigators. In clinical trials at day 30, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance as compared to 7% (9/132) in placebo, as evaluated by patients. (1)
Reference: (1) BOTOX® Cosmetic Prescribing Information, October 2017.
